nday
CVE-2025-3586

Liferay Portal / DXP: broken access controlnday가 생성한 제목입니다. CVE 레코드에는 제목이 없습니다.

Liferay / Portal, DXP

CVE 공개: . nday가 아직 패치 근거를 수집하지 않았습니다. 패치가 없다는 뜻은 아닙니다. PoC 출처 4곳 모두 미등재. CISA KEV 미등재.

why these tags

nday derives these tags by fixed rules from the facts below; NVD, the CNA and other sources do not assign them. Vocabulary and rules: ~/tags.

broken access control
CWE-863, stated by the CNA Liferay 및 NVD, republishing [email protected]
network
AV:N in CVSS:4.0/AV:N/AC:H/AT:N/PR:H/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N (CVSS 4.0) from the CNA Liferay
no user interaction
UI:N in CVSS:4.0/AV:N/AC:H/AT:N/PR:H/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N (CVSS 4.0) from the CNA Liferay
Liferay Portal / DXP
affected products in the CVE record: Liferay · DXP, Liferay · PortalCPE names NVD's analysts give as vulnerable: a:liferay:digital_experience_platform, a:liferay:liferay_portal
CMS and plugins
affected products in the CVE record: Liferay · DXP, Liferay · PortalCPE names NVD's analysts give as vulnerable: a:liferay:digital_experience_platform, a:liferay:liferay_portalthe product type of Liferay Portal / DXP in nday's product registry
현재 단계
DIS
공개
CVSS
7.5 HIGH v4.0

생명주기

가로축 UTC. 점 = 분 단위, 넓은 막대 = 날짜만, 빈 표시 = 불명 또는 추정.
시점 알 수 없음
DIS공개
2025-09-01T18:07Z
PAT패치
아직 기록 없음
ANA분석
아직 기록 없음
POCPoC
아직 기록 없음
ITW악용
아직 기록 없음
KEVKEV
아직 기록 없음

요약

In Liferay Portal 7.4.3.27 through 7.4.3.42, and Liferay DXP 2024.Q1.1 through 2024.Q1.20, 2023.Q4.0 through 2023.Q4.10, 2023.Q3.1 through 2023.Q3.10, 7.4 update 27 through update 42 (Liferay PaaS, and Liferay Self-Hosted), the Objects module does not restrict the use of Groovy scripts in Object actions for Admin Users. This allows remote authenticated admin users with the Instance Administrator role to execute arbitrary Groovy scripts (i.e., remote code execution) through Object actions.

In contrast, in Liferay DXP (Liferay SaaS), the use of Groovy in Object actions is not allowed due to the high security risks it poses.

Starting from Liferay DXP 2024.Q2 and later, a new feature has been introduced in Instance Settings that allows administrators to configure whether Groovy scripts are allowed in their instances.

Original text of the CVE record (cvelist), shown as published.

Exploit conditions

What an attack needs, read from the CVSS vector.
Attack vector AV:N
Network: the attacker only needs to reach it over the network
Attack complexity AC:H
High: the attacker must evade or get around security measures such as ASLR or DEP, or obtain target-specific secrets
Attack requirements AT:N
None: success does not depend on how the target is deployed or running
Privileges required PR:H
High: administrative or similar privileges
User interaction UI:N
None: no action by anyone other than the attacker

CVSS:4.0/AV:N/AC:H/AT:N/PR:H/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N

CVSS 4.0 vector from the CVE record, scored by the CNA Liferay.

이벤트 로그

+DISCVE 공개

CVE 레코드 공개(CNA: Liferay). CVSS 7.5(높음).

출처 cvelist · nday 일괄 수집 · 원본
{
  "id": 351856,
  "type": "disclosed",
  "source": "cvelist",
  "url": "https://www.cve.org/CVERecord?id=CVE-2025-3586",
  "occurred_at": "2025-09-01T18:07:56.434Z",
  "observed_at": "2026-11-13T05:38:48.939217Z",
  "is_backfill": true,
  "dedupe_key": "",
  "detail": {
    "cvss": {
      "source": "cna",
      "vector": "CVSS:4.0/AV:N/AC:H/AT:N/PR:H/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N",
      "version": "4.0",
      "base_score": 7.5,
      "base_severity": "HIGH"
    },
    "ssvc": {
      "timestamp": "2025-09-03T03:55:32.956265Z",
      "automatable": "no",
      "exploitation": "none",
      "technical_impact": "total"
    },
    "state": "PUBLISHED",
    "date_published": "2025-09-01T18:07:56.434Z",
    "assigner_short_name": "Liferay"
  }
}

Report an error

report an error or omission

Something on this page wrong or missing? Tell the editors; if they accept it, this page's revision log says so publicly. Upstream data is not changed.

연구자 논의

최근 7일간 연구자 0명이 언급

목록의 연구자가 X에서 이 CVE를 언급한 게시물입니다. 원문 그대로 보여 주며 nday는 검증하지 않습니다.

명단의 연구자가 X에서 이 CVE를 언급한 게시물은 아직 수집되지 않았습니다.

Discussion

0 comments

No comments yet.